MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Cardiac-Assist Devices and FDA Efforts

Article-Cardiac-Assist Devices and FDA Efforts

Originally Published MX September/October 2005


Return to Article:
Affairs of the Heart

Cardiac—assist devices--life-supporting products that incorporate a wide range of complex technologies—face a difficult regulatory environment. But according to D. Keith Grossman, CEO of Thoratec Corp. (Pleasanton, CA), the current clinical trials for his company's next-generation product are evidence of FDA's efforts to work with industry and clinicians in shortening the time-to-market for such products.

Thoratec's present version of its HeartMate left ventricular assist device (LVAD) is currently the only product to have FDA approval for destination therapy. Destination therapy refers to the device's use as a long-term permanent implant, designed for late-stage heart failure patients who do not qualify for transplants.

The new version of the device, HeartMate II, is currently being tested in pivotal clinical trials for both bridge-to-transplantation and destination-therapy indications. According to Thoratec, the current trials mark the first time that FDA has approved a clinical trial design that includes both indications in a single protocol.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.